The Relationship Between Pre‐Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer
Clinical and Translational Science · 2026-11 · 19 (11)
DOI: 10.1111/cts.70777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 14.11.2026. Verfasst von Sybrand W J Zielhuis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Ipilimumab, Nivolumab, Urologic Neoplasms. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Patients with locoregionally advanced urothelial cancer (UC) received three pre‐operative cycles of ipilimumab and nivolumab in the NABUCCO trial, across three cohorts with different dosing combinations. This study aimed to define the pharmacokinetics (PK) of both drugs in this population and to assess the relationship between the PK and treatment response. Ipilimumab and nivolumab serum concentrations were measured in 139 samples of 52 patients. A population PK model was developed for both drugs using nonlinear mixed‐effects modeling. This model was used to examine baseline clearance (CL 0 )– and exposure‐response relationships, with pathological response at surgery as efficacy parameter. A logistic regression model was constructed to quantify these relationships. The developed population PK model adequately described ipilimumab and nivolumab observations. Individual CL 0 estimates of both drugs were correlated (correlation coefficient = 0.57). Among patients in the lowest quartile of CL 0 of both drugs, twelve out of thirteen patients were responders. In the logistic regression model, a relatively low nivolumab CL 0 and high ipilimumab exposure were successfully related to treatment response. The model predicted probability of response was higher for high‐dose ipilimumab (3 mg/kg) compared to low‐dose ipilimumab (1 mg/kg) (54% vs. 29%, respectively), and was in line with NABUCCO trial outcomes. These results support the hypothesis that for ipilimumab, an exposure‐response relationship exists, while this is not the case for nivolumab. Further confirmation of these relationships is warranted, given the limited number of patients included in the analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Department of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
ORCID-Profile: Sybrand W J Zielhuis, Karen A M de Jong, Hinke Huisman-Siebinga, Lisa T van der Heijden, Bart A W Jacobs, Jos H Beijnen, Hilde Rosing, Chantal F Stockem, Jeroen van Dorp, Michiel S van der Heijden, Alwin D R Huitema
Zitieren
APA
Zielhuis, S. W. J., de Jong, K. A. M., Huisman-Siebinga, H., van der Heijden, L. T., Jacobs, B. A. W., Beijnen, J. H., Rosing, H., Stockem, C. F., van Dorp, J., van der Heijden, M. S., & Huitema, A. D. R. (2026). The Relationship Between Pre‐Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer. Clinical and Translational Science, 19(11). https://doi.org/10.1111/cts.70777
Vancouver
Zielhuis SWJ, de Jong KAM, Huisman-Siebinga H, van der Heijden LT, Jacobs BAW, Beijnen JH, et al. The Relationship Between Pre‐Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer. Clinical and Translational Science. 2026;19(11). doi:10.1111/cts.70777
BibTeX
@article{Zielhuis2026,
author = {Zielhuis, Sybrand W J and de Jong, Karen A M and Huisman-Siebinga, Hinke and van der Heijden, Lisa T and Jacobs, Bart A W and Beijnen, Jos H and Rosing, Hilde and Stockem, Chantal F and van Dorp, Jeroen and van der Heijden, Michiel S and Huitema, Alwin D R},
title = {The Relationship Between Pre‐Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {11},
doi = {10.1111/cts.70777}
}
EUVIMED